Avalo Therapeutics, Inc.
AVTXDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How AVTX's past catalysts played out
FP01
Chronic Refractory Cough
AVTX-002
Non-Eosinophilic Asthma
CERC-301
Major Depressive Disorder
AVTX-009 Regimen 1
Hidradenitis Suppurativa
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FP01 | Phase 2 | Chronic Refractory Cough | - | - |
AVTX-002 | Phase 2 | Non-Eosinophilic Asthma | - | - |
CERC-301 | Phase 2 | Major Depressive Disorder | - | - |
AVTX-009 Regimen 1 | Phase 2 | Hidradenitis Suppurativa | - | - |
Frequently asked questions
What is in Avalo Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Avalo Therapeutics, Inc.'s (AVTX) pipeline across Phase 2. Its lead program is FP01 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Avalo Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Avalo Therapeutics, Inc. (AVTX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track AVTX biotech catalysts?→
Add AVTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Avalo Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.